CoMFA analysis of dual/multiple PPAR activators.

Dual or multiple activators are agents which act at more than one biological target and produce synergistic therapeutic effect. Computational methods can be successfully employed in designing dual activators. 'Additivity of molecular fields' concept was recently introduced to help design new dual activators. This concept is employed in this work to explore the scope and limitations of the concept, with the help of reported PPARalpha/gamma/delta multiple activators. Three individual CoMFA models were first generated, followed by dual and multiple models. Dual PPARalpha/gamma CoMFA model could be developed successfully. However, dual PPARgamma/delta, dual PPARalpha/delta and multiple PPARalpha/gamma/delta CoMFA models could not be very well developed. This follows from the poor correlation observed in the PPARdelta CoMFA model.

[1]  C. Cerletti,et al.  Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. , 2003, Trends in pharmacological sciences.

[2]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  V. Cody,et al.  Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. , 2000, Journal of medicinal chemistry.

[4]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[5]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[6]  E. Knaus,et al.  Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl)pyridine-5-carboxylate racemates, enantiomers, and diastereomers. , 2004, Journal of medicinal chemistry.

[7]  T. Willson,et al.  Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ , 2001 .

[8]  J. Auwerx,et al.  Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones , 1997, Current Pharmaceutical Design.

[9]  T. Moon,et al.  Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells. , 2004, Biological & pharmaceutical bulletin.

[10]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[11]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[12]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Rakesh Kumar,et al.  Synthesis, in vitro and in silico evaluation of l-tyrosine containing PPARα/γ dual agonists , 2007 .

[14]  Igor I Baskin,et al.  Selectivity fields: comparative molecular field analysis (CoMFA) of the glycine/NMDA and AMPA receptors. , 2003, Journal of medicinal chemistry.

[15]  P. Bharatam,et al.  Additivity of Molecular Fields: CoMFA Study on Dual Activators of PPARα and PPARγ , 2005 .

[16]  A. Mittal,et al.  Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome. , 2006, Mini reviews in medicinal chemistry.

[17]  R. Castle.  Topics in heterocyclic chemistry , 1969 .

[18]  B. Henke.  Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. , 2004, Journal of medicinal chemistry.

[19]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[20]  A. Gangjee,et al.  Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents. , 2003, Journal of Medicinal Chemistry.

[21]  R. S. Mulliken.  Electronic Population Analysis on LCAO–MO Molecular Wave Functions. I , 1955 .

[22]  C. Charlier,et al.  Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. , 2003, European journal of medicinal chemistry.

[23]  J. Lehmann,et al.  Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. , 2000, Molecular cell.